glp-1 studies Market Overview: Agonists and the Obesity Market | Blog Changes in A1C values with

The latest dual-action GLP-1 analogue, tirzepatide , which also affects GIP receptors, was approved in the US in 2022 as the drug Mounjaro for the treatment of type 2 diabetes, and in 2023 as Zepbound for the treatment of obesity and excess weight, as well as obstructive sleep apnea syndrome in obese individuals

PubMed, Garca-Martn, Elena, Pedro Ayuso, et al

The table below shows dosing for all three formulations: Egrifta SV (the current main product), Egrifta WR (a newer once-weekly-reconstitution version), and legacy Egrifta (the original 2 mg/day product used in trials)

Start with 1 teaspoon daily mixed in at least 812 oz of water